update pay ui
This commit is contained in:
477
public/htmls/医药-流感新冠.html
Normal file
477
public/htmls/医药-流感新冠.html
Normal file
@@ -0,0 +1,477 @@
|
||||
<!DOCTYPE html>
|
||||
<html lang="zh-CN" data-theme="night">
|
||||
<head>
|
||||
<meta charset="UTF-8">
|
||||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||||
<title>深度研报 | 医药-流感新冠概念</title>
|
||||
<script src="https://cdn.tailwindcss.com"></script>
|
||||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.10.2/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||||
<script defer src="https://cdn.jsdelivr.net/npm/alpinejs@3.x.x/dist/cdn.min.js"></script>
|
||||
<script src="https://cdn.jsdelivr.net/npm/echarts@5.5.0/dist/echarts.min.js"></script>
|
||||
<link rel="preconnect" href="https://fonts.googleapis.com">
|
||||
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
|
||||
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&family=Lexend:wght@300;400;500;600;700&display=swap" rel="stylesheet">
|
||||
<style>
|
||||
:root {
|
||||
--glow-color-1: rgba(79, 70, 229, 0.4); /* Indigo */
|
||||
--glow-color-2: rgba(219, 39, 119, 0.4); /* Pink */
|
||||
--glow-color-3: rgba(14, 165, 233, 0.4); /* Sky */
|
||||
}
|
||||
body {
|
||||
font-family: 'Lexend', 'Inter', sans-serif;
|
||||
background-color: #020010;
|
||||
background-image:
|
||||
radial-gradient(at 20% 15%, hsla(212, 80%, 30%, 0.1) 0px, transparent 50%),
|
||||
radial-gradient(at 80% 25%, hsla(289, 70%, 25%, 0.1) 0px, transparent 50%),
|
||||
radial-gradient(at 10% 85%, hsla(190, 80%, 35%, 0.15) 0px, transparent 50%),
|
||||
radial-gradient(at 75% 90%, hsla(340, 75%, 30%, 0.1) 0px, transparent 50%);
|
||||
color: #e2e8f0;
|
||||
}
|
||||
.glass-card {
|
||||
background: rgba(15, 23, 42, 0.3);
|
||||
backdrop-filter: blur(20px);
|
||||
-webkit-backdrop-filter: blur(20px);
|
||||
border: 1px solid rgba(255, 255, 255, 0.1);
|
||||
border-radius: 1.5rem; /* 24px */
|
||||
transition: all 0.3s ease;
|
||||
}
|
||||
.glass-card:hover {
|
||||
background: rgba(15, 23, 42, 0.5);
|
||||
border: 1px solid rgba(255, 255, 255, 0.2);
|
||||
box-shadow: 0 0 30px rgba(14, 165, 233, 0.2);
|
||||
}
|
||||
.bento-grid {
|
||||
display: grid;
|
||||
gap: 1rem;
|
||||
grid-template-columns: repeat(6, 1fr);
|
||||
}
|
||||
.bento-item {
|
||||
transition: transform 0.3s ease;
|
||||
}
|
||||
/* Spanning various columns */
|
||||
.bento-item-span-2 { grid-column: span 2; }
|
||||
.bento-item-span-3 { grid-column: span 3; }
|
||||
.bento-item-span-4 { grid-column: span 4; }
|
||||
.bento-item-span-6 { grid-column: span 6; }
|
||||
|
||||
.glow-border {
|
||||
position: relative;
|
||||
overflow: hidden;
|
||||
}
|
||||
.glow-border::before {
|
||||
content: '';
|
||||
position: absolute;
|
||||
top: 0; right: 0; bottom: 0; left: 0;
|
||||
z-index: -1;
|
||||
margin: -1px;
|
||||
border-radius: inherit;
|
||||
background: conic-gradient(from 180deg at 50% 50%, var(--glow-color-3) 0%, var(--glow-color-1) 50%, var(--glow-color-2) 100%);
|
||||
animation: spin 4s linear infinite;
|
||||
}
|
||||
@keyframes spin {
|
||||
0% { transform: rotate(0deg); }
|
||||
100% { transform: rotate(360deg); }
|
||||
}
|
||||
.section-title {
|
||||
font-size: 2.25rem;
|
||||
font-weight: 600;
|
||||
background-image: linear-gradient(90deg, #93c5fd, #a5b4fc);
|
||||
-webkit-background-clip: text;
|
||||
background-clip: text;
|
||||
color: transparent;
|
||||
text-shadow: 0 0 15px rgba(147, 197, 253, 0.3);
|
||||
}
|
||||
|
||||
.daisy-table {
|
||||
background: rgba(15, 23, 42, 0.4);
|
||||
backdrop-filter: blur(16px);
|
||||
-webkit-backdrop-filter: blur(16px);
|
||||
}
|
||||
.daisy-table th, .daisy-table td {
|
||||
border-bottom: 1px solid rgba(255, 255, 255, 0.1) !important;
|
||||
}
|
||||
.daisy-table th {
|
||||
background-color: rgba(30, 41, 59, 0.5);
|
||||
color: #cbd5e1;
|
||||
}
|
||||
|
||||
.daisy-collapse {
|
||||
background: rgba(30, 41, 59, 0.5);
|
||||
border: 1px solid rgba(255, 255, 255, 0.1);
|
||||
}
|
||||
.daisy-collapse-title {
|
||||
color: #e2e8f0;
|
||||
}
|
||||
|
||||
@media (max-width: 1024px) {
|
||||
.bento-grid { grid-template-columns: repeat(1, 1fr); }
|
||||
.bento-item-span-2, .bento-item-span-3, .bento-item-span-4, .bento-item-span-6 { grid-column: span 1; }
|
||||
}
|
||||
</style>
|
||||
</head>
|
||||
<body class="min-h-screen">
|
||||
<div class="absolute top-0 left-0 w-full h-full z-[-10] overflow-hidden">
|
||||
<div class="absolute top-[-10%] left-[-10%] w-[40vw] h-[40vw] bg-[var(--glow-color-1)] rounded-full blur-[150px] animate-[pulse_8s_ease-in-out_infinite]"></div>
|
||||
<div class="absolute bottom-[-15%] right-[-15%] w-[50vw] h-[50vw] bg-[var(--glow-color-2)] rounded-full blur-[200px] animate-[pulse_10s_ease-in-out_infinite_2s]"></div>
|
||||
</div>
|
||||
|
||||
<div class="container mx-auto p-4 md:p-8 max-w-7xl">
|
||||
<!-- Header -->
|
||||
<header class="text-center py-8 mb-8">
|
||||
<h1 class="text-4xl md:text-6xl font-bold tracking-tighter" style="background-image: linear-gradient(to right, #ffffff, #9ca3af); -webkit-background-clip: text; background-clip: text; color: transparent; text-shadow: 0 0 40px rgba(255, 255, 255, 0.2);">
|
||||
医药-流感新冠 概念
|
||||
</h1>
|
||||
<p class="mt-4 text-lg text-slate-400">深度投研数据终端</p>
|
||||
<div class="mt-2 text-xs text-slate-500 tracking-widest">北京价值前沿科技有限公司 AI投研agent：“价小前投研”</div>
|
||||
</header>
|
||||
|
||||
<!-- Insight Section -->
|
||||
<section class="mb-12">
|
||||
<h2 class="section-title mb-6">核心洞察 (Core Insight)</h2>
|
||||
<div class="bento-grid">
|
||||
<!-- 0. 概念事件 -->
|
||||
<div class="bento-item bento-item-span-6 glass-card p-6">
|
||||
<h3 class="font-bold text-xl mb-4 text-sky-300">概念演绎路径：从单一爆发到常态化共循环</h3>
|
||||
<ul class="space-y-3 text-sm text-slate-300">
|
||||
<li><strong class="text-white">2024年6月-8月 (新冠抬头期):</strong> 中疾控数据示警，新冠阳性率从8.9%升至18.7%，市场催化新冠药与检测概念股拉升。</li>
|
||||
<li><strong class="text-white">2024年9月-10月 (预期酝酿期):</strong> 流感季临近，市场进入观察与博弈阶段，主题交易活跃。</li>
|
||||
<li><strong class="text-white">2025年10月-12月 (流感爆发期 & 共振期):</strong> 南北方流感ILI%显著上升，H3N2变异毒株及国际共振（日本）引爆抗流感概念，流通股因“补库存”逻辑涨停。</li>
|
||||
<li><strong class="text-white">2025年1月 (流感高峰 & 业绩兑现期):</strong> 奥司他韦销量增长164%，流感概念持续走强，进入业绩验证阶段。</li>
|
||||
<li><strong class="text-white">2025年3月-6月 (新冠再抬头 & 逻辑切换期):</strong> 新冠阳性率再破20%，超越流感成首要病原体，市场逻辑切换至更广泛的呼吸道疾病防治。</li>
|
||||
</ul>
|
||||
</div>
|
||||
|
||||
<!-- 1. 核心观点 -->
|
||||
<div class="bento-item bento-item-span-2 glass-card p-6 flex flex-col justify-center glow-border">
|
||||
<h3 class="font-bold text-lg mb-3 text-pink-300">核心观点摘要</h3>
|
||||
<p class="text-slate-300 text-sm">概念已演变为由**季节性、周期性呼吸道疾病共循环**驱动的**常态化需求**。核心逻辑在于“症状趋同、病原体多样化”带来的**精准诊断(联检)**和**对症治疗**的确定性增量。</p>
|
||||
</div>
|
||||
|
||||
<!-- 2. 疫情趋势图 -->
|
||||
<div class="bento-item bento-item-span-4 glass-card p-6">
|
||||
<h3 class="font-bold text-lg mb-3 text-indigo-300">流感/新冠阳性率交替上升趋势</h3>
|
||||
<div id="infection-chart" class="w-full h-64"></div>
|
||||
</div>
|
||||
|
||||
<!-- 3. 核心驱动力 -->
|
||||
<div class="bento-item bento-item-span-3 glass-card p-6">
|
||||
<h3 class="font-bold text-lg mb-3 text-indigo-300">核心驱动力分析</h3>
|
||||
<ol class="list-decimal list-inside space-y-2 text-sm text-slate-300">
|
||||
<li><strong>病原学变迁:</strong> 新冠流感化，与季节性流感、RSV形成共同流行、交替感染的常态格局，支撑持续性诊疗需求。</li>
|
||||
<li><strong>临床需求升级:</strong> 从“退烧”到“确诊”。症状相似但病原体不同，治疗方案迥异，催生了对病原体精准鉴别（联检）的刚性需求。</li>
|
||||
<li><strong>民众健康意识提升:</strong> 后疫情时代，公众居家自测和备药习惯已形成，C端需求崛起。</li>
|
||||
</ol>
|
||||
</div>
|
||||
|
||||
<!-- 4. 关键催化剂 -->
|
||||
<div class="bento-item bento-item-span-3 glass-card p-6">
|
||||
<h3 class="font-bold text-lg mb-3 text-sky-300">未来关键催化剂</h3>
|
||||
<div class="space-y-2 text-sm text-slate-300">
|
||||
<p><strong class="text-white">近期 (3-6个月):</strong> ① 中疾控疫情周报数据超预期；② 联检产品、玛巴洛沙韦仿制药等新品获批上市；③ 政府集采/收储政策发布。</p>
|
||||
<p><strong class="text-white">长期:</strong> ① 诊断一体化（多靶点联检）；② 预防手段升级（mRNA/鼻喷/联合疫苗）；③ 治疗方案创新（国产1类新药）。</p>
|
||||
</div>
|
||||
</div>
|
||||
|
||||
<!-- 5. 产业链 & 核心公司 -->
|
||||
<div class="bento-item bento-item-span-6 glass-card p-6">
|
||||
<h3 class="font-bold text-xl mb-4 text-pink-300">产业链图谱与核心公司剖析</h3>
|
||||
<div class="grid grid-cols-1 md:grid-cols-3 gap-6 text-sm">
|
||||
<div>
|
||||
<h4 class="font-semibold text-white mb-2">预防 (疫苗)</h4>
|
||||
<ul class="list-disc list-inside text-slate-300">
|
||||
<li><strong>华兰疫苗:</strong> 规模化生产商，产能优势。</li>
|
||||
<li><strong>百克生物:</strong> 差异化竞争，独家鼻喷剂型，高定价。</li>
|
||||
</ul>
|
||||
</div>
|
||||
<div>
|
||||
<h4 class="font-semibold text-white mb-2">诊断 (IVD)</h4>
|
||||
<ul class="list-disc list-inside text-slate-300">
|
||||
<li><strong>九安医疗:</strong> C端出海龙头，品牌渠道优势。</li>
|
||||
<li><strong>英诺特:</strong> B端(院内)POCT联检专家。</li>
|
||||
<li><strong>圣湘生物:</strong> 分子诊断多联检布局。</li>
|
||||
</ul>
|
||||
</div>
|
||||
<div>
|
||||
<h4 class="font-semibold text-white mb-2">治疗 (药品)</h4>
|
||||
<ul class="list-disc list-inside text-slate-300">
|
||||
<li><strong>众生药业:</strong> 创新药代表，1类新药昂拉地韦。</li>
|
||||
<li><strong>华润三九:</strong> OTC品牌龙头，渠道优势。</li>
|
||||
<li><strong>以岭药业:</strong> 中成药代表，连花清瘟。</li>
|
||||
</ul>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
|
||||
<!-- 6. 投资启示与风险 -->
|
||||
<div class="bento-item bento-item-span-6 glass-card p-6">
|
||||
<h3 class="font-bold text-xl mb-4 text-sky-300">投资启示与潜在风险</h3>
|
||||
<div class="grid grid-cols-1 md:grid-cols-2 gap-6">
|
||||
<div>
|
||||
<h4 class="font-semibold text-white mb-2">最具投资价值环节</h4>
|
||||
<ul class="list-disc list-inside space-y-1 text-sm text-slate-300">
|
||||
<li><strong>呼吸道多联检 (IVD):</strong> 最具确定性的增量市场，临床刚需。</li>
|
||||
<li><strong>差异化预防产品 (疫苗):</strong> 消费升级属性，高利润率。</li>
|
||||
<li><strong>创新治疗药物:</strong> 业绩弹性最高，打开全新市场空间。</li>
|
||||
</ul>
|
||||
</div>
|
||||
<div>
|
||||
<h4 class="font-semibold text-white mb-2">潜在风险与挑战</h4>
|
||||
<ul class="list-disc list-inside space-y-1 text-sm text-slate-300">
|
||||
<li><strong>技术风险:</strong> 病毒变异导致疫苗或药物有效性下降。</li>
|
||||
<li><strong>商业化风险:</strong> 疫情“大小年”致需求波动，价格集采侵蚀。</li>
|
||||
<li><strong>预期差风险:</strong> 市场炒作热度与公司基本面脱节（如北大医药案例）。</li>
|
||||
</ul>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</section>
|
||||
|
||||
<!-- Supporting Data Section -->
|
||||
<section class="mb-12" x-data="{ activeTab: 'news' }">
|
||||
<h2 class="section-title mb-6">情报与数据支撑 (Data & Intelligence)</h2>
|
||||
<div class="space-y-4">
|
||||
<div class="daisy-collapse daisy-collapse-arrow">
|
||||
<input type="radio" name="my-accordion-2" checked="checked" />
|
||||
<div class="daisy-collapse-title text-xl font-medium">新闻情报 (News Summary)</div>
|
||||
<div class="daisy-collapse-content">
|
||||
<ul class="list-disc pl-5 space-y-2 text-slate-300 text-sm mt-4">
|
||||
<li><strong>新冠趋势:</strong> 2024年7月新冠阳性率从8.9%升至18.7%；2025年3月底至5月底，阳性率从7.5%飙升至22.8%，成为门急诊首要病原体。流行株以JN.1和XDV系列为主。</li>
|
||||
<li><strong>流感趋势:</strong> 2025年秋冬季流感活动显著上升，北方哨点ILI%达7.2%，创同期新高。主要毒株为甲型H3N2亚型（占比>95%），已出现新亚分支。</li>
|
||||
<li><strong>专家观点:</strong> 钟南山表示新冠应像流感一样对待，但需搞清诊断、针对性治疗。专家预测2025年流感季提前，高峰在12月中下旬。</li>
|
||||
<li><strong>公司动态:</strong> 奥司他韦销量激增164%；玛巴洛沙韦仿制药研发提速；众生药业、济川药业等国产创新药获批。联检成为检测趋势，九安医疗、圣湘生物等布局。</li>
|
||||
<li><strong>国际动态:</strong> 日本2025年流感季提前爆发，数据创历史新高，引发药品短缺。美国预计秋冬呼吸道疾病季与去年相似。</li>
|
||||
</ul>
|
||||
</div>
|
||||
</div>
|
||||
<div class="daisy-collapse daisy-collapse-arrow">
|
||||
<input type="radio" name="my-accordion-2" />
|
||||
<div class="daisy-collapse-title text-xl font-medium">机构路演 (Roadshow Summary)</div>
|
||||
<div class="daisy-collapse-content">
|
||||
<ul class="list-disc pl-5 space-y-2 text-slate-300 text-sm mt-4">
|
||||
<li><strong>九安医疗 (2024-10-31):</strong> 核心产品三联检（新冠+流感A/B）在美国线上线下渠道铺开，品牌优势显著，毛利率高于单检，四季度流感季有望迎来爆发，或成新爆款。</li>
|
||||
<li><strong>英诺特 (2025-01-06):</strong> 确认秋冬为呼吸道感染高发期，因症状重叠，联检需求增长。国内联检产品渗透率提升，一、四季度为销售旺季。</li>
|
||||
<li><strong>天风证券 (2024-10-20):</strong> 指出OTC感冒药持续高增，需密切观察10-11月流感数据，若不及预期，相关企业Q4业绩或承压。警惕呼吸道疾病叠加风险。</li>
|
||||
<li><strong>国联证券 (2024-03-05):</strong> 2023年多病原体叠加爆发推动相关公司业绩增长（圣湘生物呼吸道收入+600%）。呼吸道检测可能从季度性需求转为全年需求。</li>
|
||||
<li><strong>健康元 (国盛医药 2024-08-19):</strong> 对标罗氏巴洛沙韦的单剂抗流感新药上市申请获受理，III期临床达主要终点。</li>
|
||||
</ul>
|
||||
</div>
|
||||
</div>
|
||||
<div class="daisy-collapse daisy-collapse-arrow">
|
||||
<input type="radio" name="my-accordion-2" />
|
||||
<div class="daisy-collapse-title text-xl font-medium">券商研报 (Research Report Summary)</div>
|
||||
<div class="daisy-collapse-content">
|
||||
<ul class="list-disc pl-5 space-y-2 text-slate-300 text-sm mt-4">
|
||||
<li><strong>疫情态势 (2024-02-25):</strong> 北京市呈现流感和新冠共同流行的态势，新冠病毒阳性率达21.1%，JN.1为主要流行株。明确建议关注流感及新冠防治相关个股。</li>
|
||||
<li><strong>已上市药物:</strong> 新冠治疗药物包括氢溴酸氙瑞米德韦片、先诺特韦片/利托那韦片组合包装、来瑞特韦片等国产创新药。新冠疫苗中，首个sa-mRNA疫苗ARCT-154在日本获批。</li>
|
||||
<li><strong>在研药物:</strong> 君实生物的氘瑞米德韦3期临床结果积极。流感是中美创新药企共同关注的热点疾病领域。</li>
|
||||
<li><strong>前沿技术:</strong> mRNA疫苗平台、免疫激活策略、PROTAC技术等前沿平台，可能为未来广谱、快速应对流感新冠变异株提供新工具和新思路。</li>
|
||||
<li><strong>风险提示:</strong> 报告普遍提示“新冠疫情持续反复，影响行业内部分公司经营”的风险。</li>
|
||||
</ul>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</section>
|
||||
|
||||
<!-- Stock Data Section -->
|
||||
<section class="mb-12">
|
||||
<h2 class="section-title mb-6">概念核心标的 (Core Stocks)</h2>
|
||||
<div class="overflow-x-auto glass-card p-2">
|
||||
<table class="daisy-table w-full">
|
||||
<thead>
|
||||
<tr>
|
||||
<th>股票名称</th>
|
||||
<th>股票代码</th>
|
||||
<th>核心逻辑</th>
|
||||
<th>其他标签</th>
|
||||
</tr>
|
||||
</thead>
|
||||
<tbody>
|
||||
<tr><th>众生药业</th><td><a href="https://valuefrontier.cn/company?scode=002317" target="_blank" class="text-sky-400 hover:text-sky-300">002317</a></td><td>特效药</td><td class="text-rose-400">制图节点涨幅大于10%</td></tr>
|
||||
<tr><th>广生堂</th><td><a href="https://valuefrontier.cn/company?scode=300436" target="_blank" class="text-sky-400 hover:text-sky-300">300436</a></td><td>特效药</td><td class="text-rose-400">制图节点涨幅大于10%</td></tr>
|
||||
<tr><th>拓新药业</th><td><a href="https://valuefrontier.cn/company?scode=301089" target="_blank" class="text-sky-400 hover:text-sky-300">301089</a></td><td>特效药</td><td>阿兹夫定原料药唯一供应商</td></tr>
|
||||
<tr><th>九安医疗</th><td><a href="https://valuefrontier.cn/company?scode=002432" target="_blank" class="text-sky-400 hover:text-sky-300">002432</a></td><td>检测</td><td>C端联检龙头</td></tr>
|
||||
<tr><th>圣湘生物</th><td><a href="https://valuefrontier.cn/company?scode=688289" target="_blank" class="text-sky-400 hover:text-sky-300">688289</a></td><td>检测</td><td>分子诊断联检</td></tr>
|
||||
<tr><th>凯普生物</th><td><a href="https://valuefrontier.cn/company?scode=300639" target="_blank" class="text-sky-400 hover:text-sky-300">300639</a></td><td>检测</td><td class="text-rose-400">制图节点涨幅大于10%</td></tr>
|
||||
<tr><th>特一药业</th><td><a href="https://valuefrontier.cn/company?scode=002728" target="_blank" class="text-sky-400 hover:text-sky-300">002728</a></td><td>止咳药</td><td class="text-rose-400">制图节点涨幅大于10%</td></tr>
|
||||
<tr><th>以岭药业</th><td><a href="https://valuefrontier.cn/company?scode=002603" target="_blank" class="text-sky-400 hover:text-sky-300">002603</a></td><td>感冒药</td><td class="text-rose-400">制图节点涨幅大于10%</td></tr>
|
||||
<tr><th>华润三九</th><td><a href="https://valuefrontier.cn/company?scode=000999" target="_blank" class="text-sky-400 hover:text-sky-300">000999</a></td><td>感冒药</td><td>OTC龙头</td></tr>
|
||||
<tr><th>新华制药</th><td><a href="https://valuefrontier.cn/company?scode=000756" target="_blank" class="text-sky-400 hover:text-sky-300">000756</a></td><td>退烧药</td><td class="text-rose-400">制图节点涨幅大于10%</td></tr>
|
||||
<!-- Add other core stocks here if needed -->
|
||||
</tbody>
|
||||
</table>
|
||||
</div>
|
||||
</section>
|
||||
|
||||
<section>
|
||||
<h2 class="section-title mb-6">涨停复盘解析 (Rise Analysis)</h2>
|
||||
<div class="overflow-x-auto glass-card p-2">
|
||||
<table class="daisy-table w-full">
|
||||
<thead>
|
||||
<tr>
|
||||
<th>股票名称</th>
|
||||
<th>股票代码</th>
|
||||
<th>日期</th>
|
||||
<th>涨幅</th>
|
||||
<th>核心驱动解析</th>
|
||||
</tr>
|
||||
</thead>
|
||||
<tbody>
|
||||
<tr>
|
||||
<th>药易购</th>
|
||||
<td><a href="https://valuefrontier.cn/company?scode=300937" target="_blank" class="text-sky-400 hover:text-sky-300">300937</a></td>
|
||||
<td>2025-11-12</td>
|
||||
<td class="text-green-400">19.99%</td>
|
||||
<td class="text-sm">流感高峰官宣+引入战投双重催化，资金选择流通盘最小、线上批发占比最高的医药流通标的做情绪放大器。渠道库存低，具备快速补货能力。</td>
|
||||
</tr>
|
||||
<tr>
|
||||
<th>北大医药</th>
|
||||
<td><a href="https://valuefrontier.cn/company?scode=000788" target="_blank" class="text-sky-400 hover:text-sky-300">000788</a></td>
|
||||
<td>2025-11-10</td>
|
||||
<td class="text-green-400">10.02%</td>
|
||||
<td class="text-sm">流感数据跳升+中疾控要求提前备药触发，资金将其奥司他韦产能作为短期弹性标的爆炒。纯事件驱动，弹性有限。</td>
|
||||
</tr>
|
||||
<tr>
|
||||
<th>人民同泰</th>
|
||||
<td><a href="https://valuefrontier.cn/company?scode=600829" target="_blank" class="text-sky-400 hover:text-sky-300">600829</a></td>
|
||||
<td>2025-11-14</td>
|
||||
<td class="text-green-400">10.04%</td>
|
||||
<td class="text-sm">流感囤货采购（承担省级储备）+三精连锁股权并表预期叠加，极小流通盘放大弹性，成为医药商业情绪龙头。</td>
|
||||
</tr>
|
||||
<tr>
|
||||
<th>康芝药业</th>
|
||||
<td><a href="https://valuefrontier.cn/company?scode=300086" target="_blank" class="text-sky-400 hover:text-sky-300">300086</a></td>
|
||||
<td>2025-11-14</td>
|
||||
<td class="text-green-400">20.00%</td>
|
||||
<td class="text-sm">海南封关政策利好+儿童流感阳性率创新高，公司手握“鼓励类产业”身份与全省60%儿童退热药产能，成为双主题最小市值标的。</td>
|
||||
</tr>
|
||||
<tr>
|
||||
<th>金迪克</th>
|
||||
<td><a href="https://valuefrontier.cn/company?scode=688670" target="_blank" class="text-sky-400 hover:text-sky-300">688670</a></td>
|
||||
<td>2025-11-10</td>
|
||||
<td class="text-green-400">20.01%</td>
|
||||
<td class="text-sm">“流感大年”预期升温+公司四价流感疫苗III期揭盲临近传闻，资金抢筹A股弹性最大纯流感疫苗标的。</td>
|
||||
</tr>
|
||||
</tbody>
|
||||
</table>
|
||||
</div>
|
||||
</section>
|
||||
|
||||
<!-- Footer -->
|
||||
<footer class="text-center py-12 mt-8 text-xs text-slate-500">
|
||||
<p>由北京价值前沿科技有限公司 AI投研agent：“价小前投研”进行投研呈现。</p>
|
||||
<p class="mt-1">本报告基于公开数据由AI合成，相关信息仅供参考，不构成任何投资建议，投资需谨慎。</p>
|
||||
</footer>
|
||||
</div>
|
||||
<script>
|
||||
document.addEventListener('DOMContentLoaded', function () {
|
||||
var chartDom = document.getElementById('infection-chart');
|
||||
var myChart = echarts.init(chartDom, 'dark');
|
||||
var option;
|
||||
|
||||
option = {
|
||||
backgroundColor: 'transparent',
|
||||
tooltip: {
|
||||
trigger: 'axis',
|
||||
axisPointer: {
|
||||
type: 'cross',
|
||||
label: {
|
||||
backgroundColor: '#6a7985'
|
||||
}
|
||||
}
|
||||
},
|
||||
legend: {
|
||||
data: ['新冠阳性率', '北方流感ILI%'],
|
||||
textStyle: {
|
||||
color: '#ccc'
|
||||
}
|
||||
},
|
||||
grid: {
|
||||
left: '3%',
|
||||
right: '4%',
|
||||
bottom: '3%',
|
||||
containLabel: true
|
||||
},
|
||||
xAxis: [
|
||||
{
|
||||
type: 'category',
|
||||
boundaryGap: false,
|
||||
data: ['2024-07', '2024-12', '2025-03', '2025-04', '2025-05', '2025-06'],
|
||||
axisLine: {
|
||||
lineStyle: {
|
||||
color: 'rgba(255,255,255,0.3)'
|
||||
}
|
||||
}
|
||||
}
|
||||
],
|
||||
yAxis: [
|
||||
{
|
||||
type: 'value',
|
||||
name: '百分比(%)',
|
||||
axisLabel: {
|
||||
formatter: '{value} %'
|
||||
},
|
||||
axisLine: {
|
||||
lineStyle: {
|
||||
color: 'rgba(255,255,255,0.3)'
|
||||
}
|
||||
},
|
||||
splitLine: {
|
||||
lineStyle: {
|
||||
color: 'rgba(255,255,255,0.1)'
|
||||
}
|
||||
}
|
||||
}
|
||||
],
|
||||
series: [
|
||||
{
|
||||
name: '新冠阳性率',
|
||||
type: 'line',
|
||||
stack: 'Total',
|
||||
smooth: true,
|
||||
lineStyle: {
|
||||
width: 2
|
||||
},
|
||||
showSymbol: false,
|
||||
areaStyle: {
|
||||
opacity: 0.8,
|
||||
color: new echarts.graphic.LinearGradient(0, 0, 0, 1, [
|
||||
{ offset: 0, color: 'rgba(219, 39, 119, 0.5)' },
|
||||
{ offset: 1, color: 'rgba(219, 39, 119, 0)' }
|
||||
])
|
||||
},
|
||||
emphasis: {
|
||||
focus: 'series'
|
||||
},
|
||||
data: [18.7, null, 7.5, 12.0, 16.2, 22.8]
|
||||
},
|
||||
{
|
||||
name: '北方流感ILI%',
|
||||
type: 'line',
|
||||
stack: 'Total',
|
||||
smooth: true,
|
||||
lineStyle: {
|
||||
width: 2
|
||||
},
|
||||
showSymbol: false,
|
||||
areaStyle: {
|
||||
opacity: 0.8,
|
||||
color: new echarts.graphic.LinearGradient(0, 0, 0, 1, [
|
||||
{ offset: 0, color: 'rgba(14, 165, 233, 0.5)' },
|
||||
{ offset: 1, color: 'rgba(14, 165, 233, 0)' }
|
||||
])
|
||||
},
|
||||
emphasis: {
|
||||
focus: 'series'
|
||||
},
|
||||
data: [null, 7.2, null, null, null, null]
|
||||
}
|
||||
]
|
||||
};
|
||||
|
||||
option && myChart.setOption(option);
|
||||
window.addEventListener('resize', myChart.resize);
|
||||
});
|
||||
</script>
|
||||
</body>
|
||||
</html>
|
||||
Reference in New Issue
Block a user